| (19) |
 |
|
(11) |
EP 3 754 017 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
31.03.2021 Bulletin 2021/13 |
| (43) |
Date of publication A2: |
|
23.12.2020 Bulletin 2020/52 |
| (22) |
Date of filing: 20.08.2015 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
|
Designated Validation States: |
|
MA |
| (30) |
Priority: |
21.08.2014 IL 23424614
21.08.2014 US 201462039989 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
15781152.2 / 3194586 |
| (71) |
Applicant: Omrix Biopharmaceuticals Ltd. |
|
Rehovot 7610601 (IL) |
|
| (72) |
Inventors: |
|
- PILPEL, Yair
7655923 Rehovot (IL)
- DORON, Sivan
7986400 Moshav Arugot (IL)
- ZHERDEV, Yuri
7628803 Rehovot (IL)
- BYK-TENNENBAUM, Tamara
5527809 Kiryat Ono (IL)
|
| (74) |
Representative: Kirsch, Susan Edith |
|
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB) |
|
| |
|
(57) The present invention is directed to compounds, methods for stabilizing thrombin
activity with a thrombin binding oligonucleotide and to stabilized thrombin. The thrombin
binding oligonucleotide is capable of inhibiting thrombin activity whereby the inhibition
can be reversed with an antisense oligonucleotide.